Novartis Hid Manipulated Data While Seeking Approval for $2.1 Million Treatment
The drug maker Novartis concealed manipulated data from the Food and Drug Administration while applying for approval of an extremely expensive gene therapy treatment and then delayed reporting the issue, the agency said on Tuesday. Officials said the inaccurate data, which involved testing in mice of two different strengths of the treatment, did not affect…
Details